Elledge RM - Search Results

1

bcl-2 and apoptosis in lymph node positive breast carcinoma.

Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. Berardo MD, et al. Among authors: elledge rm. Cancer. 1998 Apr 1;82(7):1296-302. Cancer. 1998. PMID: 9529021

2

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.

Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R. Massarweh S, et al. Breast Cancer Res Treat. 2011 Oct;129(3):819-27. doi: 10.1007/s10549-011-1679-8. Epub 2011 Jul 27. Breast Cancer Res Treat. 2011. PMID: 21792626 Free PMC article. Clinical Trial.

3

A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.

Niravath P, Tham YL, Wang T, Rodriguez A, Foreman C, Hilsenbeck SG, Elledge R, Rimawi M. Niravath P, et al. Oncologist. 2015 Jan;20(1):13. doi: 10.1634/theoncologist.2014-0278. Epub 2014 Nov 6. Oncologist. 2015. PMID: 25378456 Free PMC article. Clinical Trial.

4

Primary breast cancer phenotypes associated with propensity for central nervous system metastases.

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Tham YL, et al. Cancer. 2006 Aug 15;107(4):696-704. doi: 10.1002/cncr.22041. Cancer. 2006. PMID: 16826579 Free article.

5

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.

Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Howell A, et al. Among authors: elledge rm. Cancer. 2005 Jul 15;104(2):236-9. doi: 10.1002/cncr.21163. Cancer. 2005. PMID: 15937908 Free article. Clinical Trial.

6

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Arpino G, et al. Among authors: elledge rm. J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249. J Natl Cancer Inst. 2005. PMID: 16145046

7

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM. Rimawi MF, et al. Among authors: elledge rm. Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816. Cancer. 2010. PMID: 20082448 Free PMC article.

8

Association of surgery with improved survival in stage IV breast cancer patients.

Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Blanchard DK, et al. Among authors: elledge rm. Ann Surg. 2008 May;247(5):732-8. doi: 10.1097/SLA.0b013e3181656d32. Ann Surg. 2008. PMID: 18438108

9

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.

Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC. Nguyen DM, et al. Among authors: elledge rm. Clin Cancer Res. 2006 Sep 1;12(17):5047-54. doi: 10.1158/1078-0432.CCR-05-2248. Clin Cancer Res. 2006. PMID: 16951220

10

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.

Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC. Tham YL, et al. Among authors: elledge rm. Breast Cancer Res Treat. 2005 Dec;94(3):279-84. doi: 10.1007/s10549-005-9020-z. Breast Cancer Res Treat. 2005. PMID: 16261403 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results